Genfit SA (GNFT) AI Stock Analysis

• Market Cap: $174.38M
• Dividend Yield: N/A
• Average Volume (3M): 15.14K
• Price to Earnings (P/E): 6.8
• Beta (1Y): 0.56
• Revenue Growth: 243.10%
• EPS Growth: N/A
• Country: US
• Employees: 169
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): 0.48
• Shares Outstanding: 49,996,185
• 10 Day Avg. Volume: 27,747
• 30 Day Avg. Volume: 15,142
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 5.80
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.00
• Price Target Upside: 257.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Genfit SA's stock score reflects significant financial challenges, particularly in profitability and cash flow. While the stock may be undervalued, negative technical trends and the absence of earnings call guidance contribute to a cautious outlook. Improvements in financial health and clearer strategic direction are needed for a more favorable assessment.

Positive Factors

Debt Management

Plans to eliminate outstanding convertible debt should provide further capital flexibility for the company moving forward.

Financial Stability

GENFIT entered into a royalty financing agreement with HealthCare Royalty (HCRx) for up to €185M in total funding, providing financial stability and resources for future projects.

Research and Development

GENFIT announced a list of its 2025 milestones that includes up to four clinical data readouts from its Acute on-Chronic Liver Failure (ACLF) programs, indicating progress in their research and development efforts.

Negative Factors

Financial Risk

Planned financing could extend GENFIT's cash runway beyond 2027, alleviating financial concerns and supporting long-term operations.

Genfit SA Business Overview & Revenue Model

Company Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

How the Company Makes Money

Genfit SA makes money primarily through the development and commercialization of its pharmaceutical products and diagnostic solutions. The company generates revenue from licensing agreements, partnerships with other pharmaceutical companies, and sales of its diagnostic tools. Key revenue streams include milestone payments and royalties from collaborative agreements, particularly those related to the development and commercialization of its drug candidates. Significant partnerships with larger pharmaceutical companies help enhance its research capabilities and expand its market reach, contributing to its earnings. Additionally, Genfit may also receive government grants or research funding to support its projects, although these are typically a smaller component of its overall revenue model.

Genfit SA Financial Statement Overview

Summary

Genfit SA faces financial challenges with negative profitability and cash flow issues. While revenue has rebounded, it remains below previous levels. The balance sheet shows some stabilization, but high debt is a concern.

Income Statement

Genfit SA's income statement shows a challenging period with significant fluctuations. The gross profit margin remained strong, but the net profit margin was negative due to substantial losses, reflecting ongoing financial challenges. Revenue showed a rebound in 2023 from 2022 but remains below 2021 levels, indicating instability. The EBIT and EBITDA margins were both negative, underscoring operational inefficiencies and ongoing struggles to achieve profitability.

Balance Sheet

The company's balance sheet reflects a moderate position. The debt-to-equity ratio has improved, but remains an area of concern, indicating a reliance on debt financing. The return on equity has been negative, reflecting recent losses. However, the equity ratio has improved from negative to positive, showcasing some stability in its financial structure.

Cash Flow

Cash flow analysis reveals significant challenges for Genfit SA. The free cash flow growth rate is negative, indicating cash outflows exceeding inflows. The operating cash flow to net income ratio is negative due to losses, and the free cash flow to net income ratio is unfavorable, highlighting ongoing cash management issues and the need for improved cash flow generation.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
78.19M	28.57M	20.20M	80.07M	765.00K	30.84M
	Gross Profit
77.32M	28.22M	19.95M	79.91M	563.00K	30.66M
	EBIT
14.89M	-26.58M	-27.55M	76.74M	-77.79M	-57.83M
	EBITDA
24.65M	-22.24M	-23.60M	34.91M	-91.14M	-51.02M
	Net Income Common Stockholders
22.27M	-28.89M	-23.72M	67.26M	-101.22M	-65.14M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
13.94M	77.79M	140.55M	258.76M	171.03M	276.75M
	Total Assets
31.39M	173.87M	215.54M	281.72M	198.61M	309.85M
	Total Debt
0.00	70.18M	75.28M	74.23M	185.69M	183.62M
	Net Debt
-13.94M	-7.61M	-60.73M	-184.52M	14.66M	-93.13M
	Total Liabilities
23.00M	105.92M	121.01M	162.62M	214.78M	225.79M
	Stockholders Equity
8.39M	67.95M	94.53M	119.10M	-16.16M	84.06M
Cash Flow		Free Cash Flow
-42.69M	-57.92M	-72.64M	99.38M	-97.27M	-49.71M
	Operating Cash Flow
-41.54M	-55.43M	-72.64M	99.92M	-96.37M	-47.68M
	Investing Cash Flow
-1.14M	2.23M	-46.27M	-3.38M	-966.00K	327.00K
	Financing Cash Flow
-7.56M	-5.10M	-3.79M	-8.92M	-8.26M	116.86M

Genfit SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.64
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNFT, the sentiment is Positive. The current price of 3.64 is above the 20-day moving average (MA) of 3.42, above the 50-day MA of 3.57, and below the 200-day MA of 4.23, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 53.73 is Neutral, neither overbought nor oversold. The STOCH value of 76.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNFT.

Genfit SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
GNFT	48 Neutral	$174.38M	6.77	26.13%	―	243.10%	―
AMRN	47 Neutral	$215.26M	―	-15.79%	―	-25.86%	-37.19%
IPHA	46 Neutral	$164.26M	―	-160.99%	―	-42.35%	42.43%
IKT	46 Neutral	$145.71M	―	-52.00%	―	-100.00%	38.72%
SGMO	45 Neutral	$174.44M	―	-187.83%	―	-67.20%	64.66%
FHTX	39 Underperform	$216.89M	―	322.49%	―	-33.83%	27.89%